Alterations in Creatine Kinase, Phosphate and Lipid Values in Patients With Chronic Myeloid Leukemia During Treatment With Imatinib

Haematologica - Italy
doi 10.3324/haematol.11680
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

Imatinib and Plasmacytoid Dendritic Cell Function in Patients With Chronic Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2004English

Treatment of Chronic Myeloid Leukemia With Generic Imatinib in Patients From Northeastern Part of India

International Journal of Research in Pharmaceutical Sciences
ToxicologyPharmaceuticsPharmacology
2019English

Micro-Rna Response to Imatinib Mesylate in Patients With Chronic Myeloid Leukemia

Haematologica
Hematology
2010English

Tyrosine Kinase Inhibitor Sequencing in Patients With Chronic Myeloid Leukemia

Oncology and Therapy
Oncology
2019English

Arterial Events in Patients With Chronic Myeloid Leukemia Receiving Treatment With Second Generation Tyrosine Kinase Inhibitors

Klinicheskaya Onkogematologiya/Clinical Oncohematology
OncologyHematology
2016English

CD34+/Ph+ Cells Are Still Detectable in Chronic Myeloid Leukemia Patients With Sustained and Prolonged Complete Cytogenetic Remission During Treatment With Imatinib Mesylate

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2007English

Dasatinib in the Treatment of Imatinib Refractory Chronic Myeloid Leukemia

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2009English

Pancreatic Enzyme Elevation in Chronic Myeloid Leukemia Patients Treated With Nilotinib After Imatinib Failure

Haematologica
Hematology
2009English

Prognostic Factors Associated With a Stable MR4.5 Achievement in Chronic Myeloid Leukemia Patients Treated With Imatinib

Oncotarget
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy